Anatomy & Physiology: Current Research
Open Access

Sara Shabana

Publications

• Research Article
  The Efficacy of Etoposide on H9c2 Cardiomyoblasts Against Doxorubicin Induced Cardiotoxicity
  Author(s): Sara Shabana, Suad Aden, Nabeel Abdulrahman, Sadaf Riaz, Maiy Jaballah, Iman A. Mohamed and Fatima MraicheSara Shabana, Suad Aden, Nabeel Abdulrahman, Sadaf Riaz, Maiy Jaballah, Iman A. Mohamed and Fatima Mraiche
  
  Background: Doxorubicin (DOX), a widely used anticancer drug, has been associated with cardiotoxicity. Recently, DOX-induced cardiotoxicity has been attributed to topoisomerase II (TOPII)-β expression and activity. In our study, we investigated the effect of inhibiting TOPII in attenuating the DOX induced cardiotoxicity. Method: H9c2 cardiomyoblasts were treated with 1 or 2 μM DOX (+/-) 1 μM ETO. Cardiotoxicity was assessed by examining cell viability using the MTT assay, hypertrophy of crystal violet stained cardiomyoblasts and ROSproduction. Results: DOX induced a dose dependent increase in cardiotoxicity as indicated by the significant reduction in cell viability (71.77 ± 9.25% 2 μM DOX vs. 100% control, P<0.05), ROS production and hypertrophy. Stimulation of H9c2 cardiomyoblasts with bot.. View More»
  

  Abstract PDF

Relevant Topics